$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

$bdtx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000170154121000018 Filed on March 25, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.430M	$5.550M	$4.860M
YoY Change	88.54%	120.24%	260.0%
% of Gross Profit
Research & Development	$17.76M	$12.93M	$10.17M
YoY Change	138.07%	129.48%	80.13%
% of Gross Profit
Depreciation & Amortization	$10.00K	$20.00K	$10.00K
YoY Change	0.0%	100.0%	-50.0%
% of Gross Profit
Operating Expenses	$23.18M	$18.48M	$15.03M
YoY Change	124.12%	126.8%	114.72%
Operating Profit	-$23.18M	-$18.48M	-$15.03M
YoY Change	124.12%	126.8%	114.72%
Interest Expense	$1.250M	$0.00	$1.000K
YoY Change	171.74%
% of Operating Profit
Other Income/Expense, Net	-$700.0K	$568.0K	$457.0K
YoY Change	-7100.0%	-150.71%	-108.64%
Pretax Income	-$22.63M	-$17.91M	-$14.57M
YoY Change	129.05%	93.2%	18.55%
Income Tax
% Of Pretax Income
Net Earnings	-$22.63M	-$17.91M	-$14.57M
YoY Change	129.12%	93.27%	18.59%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.50	-$0.41
Diluted Earnings Per Share	-$627.7K	-$0.50	-$0.41
COMMON SHARES
Basic Shares Outstanding	36.00M shares	35.93M shares	35.91M shares
Diluted Shares Outstanding		35.93M shares	35.91M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$315.1M	$333.1M	$204.5M
YoY Change	103.71%	323.22%	416.39%
Cash & Equivalents	$34.61M	$56.20M	$63.98M
Short-Term Investments	$280.5M	$276.9M	$140.5M
Other Short-Term Assets	$4.500M	$3.400M	$3.800M
YoY Change	350.0%	1033.33%	1166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$319.6M	$336.4M	$208.2M
YoY Change	105.22%	325.86%	420.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$385.0K	$229.0K	$166.0K
YoY Change	134.76%	129.0%	66.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$140.5M
YoY Change
Other Assets	$106.0K	$92.00K	$80.00K
YoY Change	79.66%	-94.59%	-20.0%
Total Long-Term Assets	$10.12M	$10.01M	$141.2M
YoY Change	291.94%	488.65%	70502.5%
TOTAL ASSETS
Total Short-Term Assets	$319.6M	$336.4M	$208.2M
Total Long-Term Assets	$10.12M	$10.01M	$141.2M
Total Assets	$329.7M	$346.4M	$349.5M
YoY Change	108.26%	329.29%	769.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.538M	$2.932M	$45.00K
YoY Change	29.23%	109.43%	-93.57%
Accrued Expenses	$11.68M	$8.219M	$6.079M
YoY Change	302.9%	310.95%	659.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.22M	$11.34M	$6.139M
YoY Change	192.37%	146.54%	309.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.700M	$7.700M	$200.0K
YoY Change			-97.85%
Total Long-Term Liabilities	$7.700M	$7.700M	$200.0K
YoY Change			-97.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.22M	$11.34M	$6.139M
Total Long-Term Liabilities	$7.700M	$7.700M	$200.0K
Total Liabilities	$21.91M	$19.09M	$6.325M
YoY Change	349.11%	306.17%	-41.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.2M	-$95.60M	-$77.69M
YoY Change	131.95%
Common Stock	$5.000K	$5.000K	$5.000K
YoY Change	400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$307.8M	$327.3M	$343.1M
YoY Change
Total Liabilities & Shareholders Equity	$329.7M	$346.4M	$349.5M
YoY Change	108.26%	329.29%	769.28%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$22.63M	-$17.91M	-$14.57M
YoY Change	129.12%	93.27%	18.59%
Depreciation, Depletion And Amortization	$10.00K	$20.00K	$10.00K
YoY Change	0.0%	100.0%	-50.0%
Cash From Operating Activities	-$15.78M	-$11.48M	-$13.57M
YoY Change	110.12%	117.42%	171.4%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	$0.00	-$30.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$6.540M	$4.610M	-$279.6M
YoY Change		-15466.67%
Cash From Investing Activities	-$6.650M	$4.600M	-$279.6M
YoY Change	-33350.0%	-15433.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	830.0K	270.0K	0.000
YoY Change	-99.01%	-99.39%	-100.0%
NET CHANGE
Cash From Operating Activities	-15.78M	-11.48M	-13.57M
Cash From Investing Activities	-6.650M	4.600M	-279.6M
Cash From Financing Activities	830.0K	270.0K	0.000
Net Change In Cash	-21.60M	-6.610M	-293.2M
YoY Change	-128.42%	-116.94%	5683.23%
FREE CASH FLOW
Cash From Operating Activities	-$15.78M	-$11.48M	-$13.57M
Capital Expenditures	-$110.0K	$0.00	-$30.00K
Free Cash Flow	-$15.67M	-$11.48M	-$13.54M
YoY Change	108.66%	117.84%	170.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001701541
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:accruedliabilitiescurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38501
CY2020	dei	Entity Registrant Name EntityRegistrantName	BLACK DIAMOND THERAPEUTICS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4254660
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Main Street, 10th Floor
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020	dei	City Area Code CityAreaCode	(617)
CY2020	dei	Local Phone Number LocalPhoneNumber	252-0848
CY2020	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001
CY2020	dei	Trading Symbol TradingSymbol	BDTX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1010084331	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36137635	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34605000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154666000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	280462000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4487000	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1048000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	319554000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	155714000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	385000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1223000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	55000	USD
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	2303000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8402000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	106000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59000	USD
CY2020Q4	us-gaap	Assets Assets	329670000	USD
CY2019Q4	us-gaap	Assets Assets	158295000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2538000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1964000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11680000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2899000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14218000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4863000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	16000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7694000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	21912000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	4879000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	64871795	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	194727000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	200573000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36078383	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36078383	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2236672	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2236672	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	425363000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3812000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	614000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118224000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50970000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	307758000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-47157000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329670000	USD
CY2020	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
CY2019	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	445000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158295000	USD
CY2020	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	2364000	USD
CY2019	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	9966000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48209000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21753000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21361000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7579000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	69570000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	29332000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-69570000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-29332000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1000	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4041000	USD
CY2019	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	461000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6393000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1724000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2316000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5926000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.99
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32907100	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2075753	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	614000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66640000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35258000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7765000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	3643000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6393000	USD
CY2020	us-gaap	Depreciation Depreciation	52000	USD
CY2019	us-gaap	Depreciation Depreciation	47000	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1725000	USD
CY2019	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2020	bdtx	Rent Expense RentExpense	548000	USD
CY2019	bdtx	Rent Expense RentExpense	0	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	24000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-38000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3439000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1024000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	47000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	51000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1069000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1454000	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	USD
CY2019	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-1707000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8026000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1791000	USD
CY2020	bdtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-567000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52146000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24674000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	142000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	90928000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-118893000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103061000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	372477000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281691000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21000	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	129499000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1100000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1275000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	213844000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1743000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	214944000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	127756000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35828000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154721000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51660000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35828000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154721000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34605000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154666000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1223000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	55000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154721000	USD
CY2020	bdtx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
CY2019	bdtx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	656000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	200573000	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8474000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	33668075	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	60770000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-15542000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3643000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	200573000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-47157000	USD
CY2020	bdtx	Reclassifications Of Temporary To Permanent Equity Shares ReclassificationsOfTemporaryToPermanentEquityShares	64839353	shares
CY2020	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	200573000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200573000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	212101000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	16000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1100000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7765000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	614000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	307758000	USD
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.01581
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock before the Company’s initial public offering, the valuation of stock-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1223000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	55000	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains accounts for all cash and cash equivalents at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div>
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	2303000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4023000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	6393000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	10400000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	16000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	279848000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	651000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	37000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280462000	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	549000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	164000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	112000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	385000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2020	us-gaap	Depreciation Depreciation	52000	USD
CY2019	us-gaap	Depreciation Depreciation	47000	USD
CY2020Q4	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	5102000	USD
CY2019Q4	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	434000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3729000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1182000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1603000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	984000	USD
CY2020Q4	bdtx	Accrued Legal Fees Current AccruedLegalFeesCurrent	199000	USD
CY2019Q4	bdtx	Accrued Legal Fees Current AccruedLegalFeesCurrent	299000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1047000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11680000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2899000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	64871795	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	200573000	USD
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	194727000	USD
CY2019Q4	bdtx	Convertible Preferred Stock Total Shares Issuable Upon Conversion ConvertiblePreferredStockTotalSharesIssuableUponConversion	21499770	shares
CY2020Q1	bdtx	Shares Authorized SharesAuthorized	510000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0091
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0168
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.638
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.622
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2378474	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.03
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6722000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1574543	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.10
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	160509	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.85
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39764	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.11
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752744	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.71
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62842000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3752744	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.71
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.20
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	62842000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	706696	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y7M6D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	17226000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.18
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.82
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4198000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	319000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7765000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3643000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.13
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	28388000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
CY2020	bdtx	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.008
CY2019	bdtx	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.042
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.022
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.016
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.265
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.198
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24059000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9512000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2477000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1014000	USD
CY2020Q4	bdtx	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2147000	USD
CY2019Q4	bdtx	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	680000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	280000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1434000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	196000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30797000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11002000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28709000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10995000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2088000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2063000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	25000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17714000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32907100	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2075753	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.99
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3817837	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23889001	shares
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1298000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1331000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1364000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3803000	USD
CY2020	bdtx	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	3	contract
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	767000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	769000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	44000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1580000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	432000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1485000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1343000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	12879000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	15028000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	18480000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10624000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1883000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8741000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	223000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	228000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	77000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	528000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1545000	USD
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	415000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	23183000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	69570000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12879000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15028000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18480000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-23183000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	592000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q4	bdtx	Prepaid Expense Related Party Current PrepaidExpenseRelatedPartyCurrent	916000	USD
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2364000	USD
CY2019	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	10411000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-69570000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12145000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-14571000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-17912000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-22626000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-67254000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	3841000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	6999000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	8148000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	10344000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	29332000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3841000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6999000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8148000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10344000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-29332000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3828000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-12287000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9268000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-9875000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-35258000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.87
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.99
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.50
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.63
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.99

Files In Submission

Name	View Source	Status
0001701541-21-000018-index-headers.html	Edgar Link	pending
0001701541-21-000018-index.html	Edgar Link	pending
0001701541-21-000018.txt	Edgar Link	pending
0001701541-21-000018-xbrl.zip	Edgar Link	pending
bdtx-20201231.htm	Edgar Link	pending
bdtx-20201231.xsd	Edgar Link	pending
bdtx-20201231_cal.xml	Edgar Link	unprocessable
bdtx-20201231_def.xml	Edgar Link	unprocessable
bdtx-20201231_g1.jpg	Edgar Link	pending
bdtx-20201231_g10.jpg	Edgar Link	pending
bdtx-20201231_g11.jpg	Edgar Link	pending
bdtx-20201231_g12.jpg	Edgar Link	pending
bdtx-20201231_g13.jpg	Edgar Link	pending
bdtx-20201231_g14.jpg	Edgar Link	pending
bdtx-20201231_g15.jpg	Edgar Link	pending
bdtx-20201231_g16.jpg	Edgar Link	pending
bdtx-20201231_g17.jpg	Edgar Link	pending
bdtx-20201231_g2.jpg	Edgar Link	pending
bdtx-20201231_g3.jpg	Edgar Link	pending
bdtx-20201231_g4.jpg	Edgar Link	pending
bdtx-20201231_g5.jpg	Edgar Link	pending
bdtx-20201231_g6.jpg	Edgar Link	pending
bdtx-20201231_g7.jpg	Edgar Link	pending
bdtx-20201231_g8.jpg	Edgar Link	pending
bdtx-20201231_g9.jpg	Edgar Link	pending
bdtx-20201231_htm.xml	Edgar Link	completed
bdtx-20201231_lab.xml	Edgar Link	unprocessable
bdtx-20201231_pre.xml	Edgar Link	unprocessable
exhibit1011_q42020.htm	Edgar Link	pending
exhibit231_q42020.htm	Edgar Link	pending
exhibit311_q42020.htm	Edgar Link	pending
exhibit312_q42020.htm	Edgar Link	pending
exhibit321_q42020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

2020 Q4 Form 10-K Financial Statement

#000170154121000018 Filed on March 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX Black Diamond Therapeutics Inc Stock $bdtx

2020 Q4 Form 10-K Financial Statement

#000170154121000018 Filed on March 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx